Abstract:Henning Søndergaard Danish Kidney Association, Taastrup, Denmark Correspondence: Henning Søndergaard, Danish Kidney Association, Blekinge Blvd. 2, 2630 Taastrup, Denmark, Tel +45 61654865, Email The inclusion of patient representatives as study consultants brings diverse perspectives, insights, and experiences to clinical trial design and execution, and their role in the clinical trial development process is being increasingly recognized and valued. The APPETIZE study evaluated the palatability of, and preference for, three potassium binders for treating hyperkalemia in patients with chronic kidney disease. A core aspect of the development of this study was the inclusion of a patient representative during the design stage. Here, I describe the process of patient involvement in the APPETIZE study design (ClinicalTrials.gov Identifier: NCT04566653), the resultant positive impacts, and key learnings. A patient with chronic kidney disease was invited to be a member of the APPETIZE trial design team. This patient representative attended study team meetings and provided invaluable input into protocol development, questionnaire selection, design of patient information sheets and consent forms, and primary manuscript structure. These critical insights resulted in an enhanced trial design and generation of high-quality, patient-relevant data. APPETIZE provides an excellent example of a patient preference study that relied on input from multiple stakeholder groups, including, most notably, the patients themselves. This approach may serve as a model for early and deep patient engagement in the design and interpretation of clinical trials. Keywords: clinical trials, patient representation, chronic kidney disease, hyperkalemia Patient participation in and contribution to the drug development cycle has historically been restricted to post-approval disease education. 1 Traditional approaches to clinical trial design considered the disease symptoms of a patient in isolation from the patient as an individual, with the primary role of the patient to adhere to prescribed treatment. 2,3 Recent changes have seen an evolution of the medical field from a "paternalistic" medical model towards a more "patient-centric" one. 2–4 Once patients are thought of as individuals rather than as a collection of clinical symptoms or laboratory values, the patient voice becomes more relevant and it becomes essential to involve patients as consultants in the design of clinical studies. Patient centricity has been defined, during consultation with key stakeholders, patients, and carers, as "putting the patient first in an open and sustained engagement of the patient to respectfully and compassionately achieve the best experience and outcome for that person and their family". 1 Patient centricity does not need to be confined solely to the healthcare setting; patient involvement and engagement can and should also be incorporated into research and all aspects of the clinical trial lifecycle (Figure 1). 5,6 The value of experience provided by patients is highlighted by the Patient-Centered Outcomes Research Institute (PCORI), who recommend that "meaningful involvement" of patients, caregivers, and clinicians should occur in the planning and conduct of clinical trials. 7 Figure 1 Patient involvement across the clinical trial lifecycle. In this paper, I introduce the importance of patient centricity in clinical trial design before summarizing the process, key changes, and lessons learned from involvement of a patient representative in the design of the APPETIZE clinical trial. Patient centricity and engagement in the context of clinical trials confers a number of benefits to different stakeholders (Figure 2). 8,9 Benefits to patients include enhanced engagement, because patient inclusion as consultants in clinical trial development offers a sense of empowerment, resulting in a more positive trial experience. 9,10 There can also be a reduced burden and improved convenience with respect to study assessments, such as flexible appointment schedules, remote monitoring options, and decreased travel requirements. 11 Patient involvement in the development of trial communication materials allows for the inclusion of more relevant information from lived patient experiences, and facilitates improved patient understanding through the use of plain language. 6,12,13 Patient representatives are well-positioned to advise on the most relevant patient-centered outcome measures, which can include improvements in health-related quality of life, symptom relief, mental health, and functional capacity, and can help ensure that trials are better able to capture the overall impact of the intervention on patients' lives. 9,12,13 Data on patient -Abstract Truncated-

Patient Preferences and Priorities for the Design of an AKI Prevention Trial: Findings from a Consensus Workshop

Recommendations for clinical trial design in acute kidney injury from the 31st acute disease quality initiative consensus conference. A consensus statement

Clinical Trial Considerations in Developing Treatments for Early Stages of Common, Chronic Kidney Diseases: A Scientific Workshop Cosponsored by the National Kidney Foundation and the US Food and Drug Administration

Early, Individualized Recommendations for Hospitalized Patients With Acute Kidney Injury: A Randomized Clinical Trial

Developing Consensus-Based Priority Outcome Domains for Trials in Kidney Transplantation: A Multinational Delphi Survey With Patients, Caregivers, and Health Professionals

Overcoming Translational Barriers in Acute Kidney Injury: A Report from an NIDDK Workshop.

Developing Consensus-Based Outcome Domains for Trials in Children and Adolescents With CKD: An International Delphi Survey

Outcomes for clinical trials involving adults with chronic kidney disease: a multinational Delphi survey involving patients, caregivers and health professionals

Participant Perceptions in a Long-term Clinical Trial of Autosomal Dominant Polycystic Kidney Disease

A Patient-Prioritized Research Agenda for Clinical Trials in Kidney Stone Disease

Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease

Identifying and integrating patient and caregiver perspectives in clinical practice guidelines for percutaneous renal biopsy

Improving Diverse and Equitable Involvement of Patients and Caregivers in Research in CKD: Report of a Better Evidence and Translation-Chronic Kidney Disease (BEAT-CKD) Workshop

A prospective clinical trial of specialist renal nursing in the primary care setting to prevent progression of chronic kidney: a quality improvement report

Perceived Significance of Engagement in Research Prioritization Among Chronic Kidney Disease Patients, Caregivers, and Health Care Professionals: A Qualitative Study

International consensus definitions of clinical trial outcomes for kidney failure: 2020

Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy

Study protocol for a multicentre randomised controlled trial: Safety, Tolerability, efficacy and quality of life Of a human recombinant alkaline Phosphatase in patients with sepsis-associated Acute Kidney Injury (STOP-AKI)

An International Delphi Survey Helped Develop Consensus-Based Core Outcome Domains for Trials in Peritoneal Dialysis

Sepsis-associated acute kidney injury: recent advances in enrichment strategies, sub-phenotyping and clinical trials

Patient Involvement in the Design of an Innovative Clinical Study to Compare the Palatability of Anti-Hyperkalemia Medications